Abstract:International Journal of DermatologyVolume 62, Issue 5 p. e293-e295 Correspondence Successful treatment of prurigo nodularis with tofacitinib: The experience from a single center Taoming Liu MD, Taoming Liu MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorYuqi Chu MD, Yuqi Chu MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorYuqian Wang MD, Yuqian Wang MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXinyue Zhong MD, Xinyue Zhong MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorChangyi Yang MD, Changyi Yang MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJuan Bai MD, Corresponding Author Juan Bai MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong Fang MD, Corresponding Author Hong Fang MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJianjun Qiao MD, PhD, Corresponding Author Jianjun Qiao MD, PhD [email protected] orcid.org/0000-0003-3386-297X Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this author Taoming Liu MD, Taoming Liu MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorYuqi Chu MD, Yuqi Chu MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorYuqian Wang MD, Yuqian Wang MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXinyue Zhong MD, Xinyue Zhong MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorChangyi Yang MD, Changyi Yang MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJuan Bai MD, Corresponding Author Juan Bai MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong Fang MD, Corresponding Author Hong Fang MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJianjun Qiao MD, PhD, Corresponding Author Jianjun Qiao MD, PhD [email protected] orcid.org/0000-0003-3386-297X Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this author First published: 27 December 2022 https://doi.org/10.1111/ijd.16568Citations: 1 Conflict of interest: None. Funding source: The National Natural Science Foundation of China (82173400 to JQ, 81972931 to HF), the Medical and Health Science and Technology Project of Health Commission of Zhejiang Province (2023KY102 to JB). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2021; 86(3): 573–80. 2Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022; 86: 414–22. 3Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020; 382: 706–16. 4Molloy OE, Kearney N, Byrne N, Kirby B. Successful treatment of recalcitrant nodular prurigo with tofacitinib. Clin Exp Dermatol. 2020; 45: 918–20. 5Peng C, Li C, Zhou Y, Wang Q, Xie P, Li T, et al. Tofacitinib for prurigo nodularis: a case report. Clin Cosmet Investig Dermatol. 2022; 15: 503–6. Citing Literature Volume62, Issue5May 2023Pages e293-e295 ReferencesRelatedInformation

A Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo

Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus

Validation of the Peak Pruritus‐Numerical Rating Scale in patients with chronic plaque psoriasis: results from a phase 2 study

Validating Patient-Reported Outcome Measures in Dermatology

Practical Use of Patient-Reported Outcome Measures in Chronic Kidney Disease-Associated Pruritus

Estimating meaningful change thresholds for Skin Pain‐Numeric Rating Scale, Sleep‐Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis

Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP)

The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control

Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)

Validation of Worst Itch Numeric Rating Scale for Prurigo Nodularis

Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

Successful Treatment of Prurigo Nodularis with Tofacitinib: the Experience from a Single Center

Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis

Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis

Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial

Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis

Content Evaluation of Pruritus, Skin Pain, and Sleep Disturbance Patient-Reported Outcome Measures in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Qualitative Interviews

Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment

Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis

Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study

Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development